Travere Therapeutics, Inc. TVTX License and collaboration revenue — Cost of goods sold
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Travere Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.
The official record: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Travere Therapeutics, Inc.'s license and collaboration revenue — cost of goods sold.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Travere Therapeutics, Inc.'s license and collaboration revenue — cost of goods sold?
- Travere Therapeutics, Inc. (TVTX) reported license and collaboration revenue — cost of goods sold of $0 in Q1 2026.
- How has Travere Therapeutics, Inc.'s license and collaboration revenue — cost of goods sold changed year-over-year?
- Travere Therapeutics, Inc.'s license and collaboration revenue — cost of goods sold decreased by 100.0% year-over-year, from $3.43M to $0.
- What does license and collaboration revenue — cost of goods sold mean?
- This metric captures the direct costs incurred to fulfill obligations associated with licensing and collaboration agreements, such as manufacturing support or technical transfer expenses. Monitoring these costs relative to segment revenue helps assess the profitability and operational efficiency of the company's partnership-based business model. Lower costs relative to revenue indicate higher margins on collaborative activities.